May 26th, 2023 (Shanghai) — We are glad to announce that Zhangming Niu, the Founder & CEO of MindRank, has been invited to present at ACCESS CHINA Boston Forum on June 4th. ACCESS CHINA Biotech Forum is the largest corporate access event between Asia and the western biopharma industry.
Please contact us if you would like to have 1 on 1 meeting with MindRank.
MindRank is an innovative drug discovery company that harnesses the power of artificial intelligence (AI) to revolutionize the drug discovery and development process. With its proprietary AI platform, Molecule Pro, the company is at the forefront of accelerating drug discovery and enabling the efficient creation of small molecule drugs with optimal efficacy and safety profiles. Molecule Pro is a cutting-edge AI platform developed by MindRank, specifically designed for molecule design and generation. By utilizing advanced algorithms and machine learning techniques, Molecule Pro has the ability to rapidly analyze vast amounts of chemical data and generate novel molecular structures with desired properties.
The primary objective of MindRank is to expedite the drug discovery process by leveraging Molecule Pro’s AI capabilities. By streamlining the identification and optimization of potential drug candidates, the company aims to significantly reduce the time and cost traditionally associated with drug discovery and development. This approach allows for faster translation of scientific discoveries into tangible therapeutic solutions, ultimately benefiting patients and addressing unmet medical needs.
MindRank’s focus on delivering small molecule drugs with desirable efficacy and safety profiles highlights its commitment to developing innovative and effective treatments. By leveraging the power of AI, the company seeks to unlock new opportunities in drug discovery and transform the way pharmaceuticals are developed and brought to market.
About the speaker
Zhangming Niu, Founder & CEO, MindRank
- Former Chief Technology Officer (CTO) of a Germany-based AI MedTech corporation from 2018 to 2020.
- Possess 11 years of industrial experience in computer science and machine learning.
- Accumulated 5 years of industrial experience specifically in artificial intelligence for drug discovery (AIDD).
- Hold a Master of Science degree obtained from Chalmers University of Technology/Karolinska Institute during the period of 2009 to 2011.
- Currently pursuing a PhD in Clinical Medicine Research using AI at Imperial College London, started in 2022.
About ACCESS CHINA Boston Forum
“ACCESS CHINA – Boston Forum @BIO” is scheduled to be held on June 4th and June 13th-15th, 2023, in Boston and online, respectively. This event is expected to be the largest Asia-themed gathering during the BIO Convention 2023. The main theme of the forum is “Building Effective Partnerships in Asia: Strategies for Collaboration and Growth”. During the forum, we will cover a range of key topics include drug innovation, market trends, partnership models, and best practices for successful collaborations, etc.
Conference Name: ACCESS CHINA – Boston Forum @BIO
Date & Time: June 4, Sun. (Boston) and June 13-15 (Online)
Content: Keynote Speeches, Panel Discussion, Company Presentations, ChemPartner-ACCESS CHINA Dinner Reception
Scale: Expected 1000 participants Online, 150 participants onsite; 100 company roadshows
Participants: Pharma/Biotech senior management and BDs, investors.
View more information at https://biotochina.org/
“ACCESS CHINA 药通中国-波士顿论坛@BIO”将于2023年6月4-15日在波士顿及线上举行的。此次论坛将是BIO Convention 2023大会期间最大的亚洲主题交流活动。在过去3年时间，药通中国已成功举办13届线上线下活动，帮助近千家公司在药通平台上展出。
大会规模：预计线上1000参会者； 线下150参会者; 100场公司路演
Register ACCESS CHINA online, please visit: ACCESS CHINA Biotech Forum
For more information, please contact: